HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 1073-1082

  Zewinger, Stephen ^a   Speer, Thimoteus ^a   Kleber, Marcus E ^a   Scharnagl, Hubert ^b   Woitas, Rainer ^c   Lepper, Philipp M ^d   Pfahler, Karolin ^a   Seiler, Sarah ^a   Heine, Gunnar H ^a   März, Winfried ^a,b,e   Silbernagel, Günther ^f   Fliser, Danilo ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF BONN   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LUDWIGSHAFEN RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; GERMANY; MORTALITY; PHYSIOLOGY; PREDICTIVE VALUE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84903309963     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013050482     Document Type: Article

References (31)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, RosamondWD, Sorlie PD, Stafford RS, Turan TN, TurnerMB,WongND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 123: e18-e209, 2011
2. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network: Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet 380: 807-814, 2012
3. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: Effects on the cardiovascular system. Circulation 116: 85-97, 2007
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847, 1998
5. FoxCS, Matsushita K,Woodward M, Bilo HJ, Chalmers J, HeerspinkHJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG; Chronic Kidney Disease Prognosis Consortium: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 380: 1662-1673, 2012
6. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, de Jong PE, Astor BC; Chronic Kidney Disease Prognosis Consortium: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis. Lancet 380: 1649-1661, 2012
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
8. SarnakMJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, KlagMJ, Parfrey P, PfefferM, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
9. US Renal Data System: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda,MD, National Institutes of HealthNational Institute of Diabetes and Digestive and Kidney Diseases, 2012
10. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl JMed 357: 1301-1310, 2007
11. Mineo C, Shaul PW: Novel biological functions of high-density lipoprotein cholesterol. Circ Res 111: 1079-1090, 2012
12. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y,Martin T, Perisa D,Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U: Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38: 754-768, 2013
13. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, LiM, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T,Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, HofkerMH,Wijmenga C, VerschurenWM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S,Willer C, Do R,Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S: Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 380: 572-580, 2012
14. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ,Mundl H, Nicholls SJ, Shah PK, Tardif JC,Wright RS; dal-OUTCOMES Investigators: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089-2099, 2012
15. Lamprea-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibley CT,O'Leary D, Sharrett AR, SzkloM: CKD, plasma lipids, and common carotid intima-media thickness: Results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7: 1777-1785, 2012
16. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C, Heinemann A, Marsche G: Uremia alters HDL composition and function. J Am Soc Nephrol 22: 1631-1641, 2011
17. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD: Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23: 934-947, 2012
18. Han CY, Chiba T, Campbell JS, FaustoN,ChaissonM,Orasanu G, Plutzky J, Chait A: Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 26: 1806-1813, 2006
19. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005
20. CharakidaM, Besler C, Batuca JR, Sangle S,Marques S, SousaM,Wang G, Tousoulis D, Delgado Alves J, Loukogeorgakis SP, Mackworth-Young C, D'Cruz D, Luscher T, Landmesser U, Deanfield JE: Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 302: 1210-1217, 2009
21. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A,Manes C, BahrMJ, Haller H, von Eckardstein A,DrexlerH, Landmesser U: Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetesmellitus but are improved after extended-release niacin therapy. Circulation 121: 110-122, 2010
22. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med 357: 2109-2122, 2007
23. Shlipak MG, Simon JA, Grady D, Lin F,Wenger NK, Furberg CD; Heart and Estrogen/progestin Replacement Study (HERS) Investigators: Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 38: 705-711, 2001
24. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135, 2011
25. Kalantar-Zadeh K, Kopple JD, KamranpourN, FogelmanAM, NavabM: HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72: 1149-1156, 2007
26. Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, Beddhu S, Nally JV Jr: Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol 8: 945-952, 2013
27. Speer T, Zewinger S, Fliser D: Uraemic dyslipidaemia revisited: Role of high-density lipoprotein. Nephrol Dial Transplant 28: 2456-2463, 2013
28. Winkelmann BR, März W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J; LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health): Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2[Suppl 1]: S1-S73, 2001
29. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, Ulrich C, Fliser D, Heine GH: CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 32: 84-92, 2011
30. Friesinger GC, Page EE, Ross RS: Prognostic significance of coronary arteriography. Trans Assoc Am Physicians 83: 78-92, 1970
31. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKDEPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367: 20-29, 2012